LncRNA CARMN inhibits the expression of matrix metalloproteinase 2 (MMP2), a protease responsible for degrading the extracellular matrix, thereby impeding the EMT process in breast cancer cells (Liao et al., 2024). The gene discussed is MMP2; the disease is breast carcinoma.